Authors
Ashley Khouri, Nathanael Jensen, Tejita Agarwal, Emily Beck, Eric Millican, Payam Tristani-Firouzi
Published in
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. Aug 03, 2026. Epub Aug 03, 2026.
Abstract
Positive margins of squamous cell carcinoma in situ or superficial basal cell carcinoma after Mohs micrographic surgery (MMS) occur in a small but clinically significant proportion of cases, with multiple management options available.
This study aimed to compare recurrence-free survival (RFS) across different treatment modalities for positive margins after MMS to inform clinical decision making.
This was a retrospective cohort study of 422 patients with positive margins after MMS from 2012 to 2022. Recurrence-free survival was analyzed using Kaplan-Meier methodology. Multivariable Cox regression adjusted for age, sex, immunosuppression, tumor characteristics, and anatomic location.
Among 388 patients in the primary analysis (306 curettage, 82 topical treatment), 3-year RFS was 92.6% (95% CI: 89.4%-95.9%) for curettage versus 82.7% (95% CI: 73.1%-93.6%) for topical treatment (p=.021). Topical treatment was independently associated with increased recurrence risk (adjusted hazard ratio 2.73, p=.021) after controlling for risk factors. Immunosuppression was the only other significant predictor of recurrence (adjusted hazard ratio 3.04, p = .036).
Curettage demonstrated superior 3-year RFS compared with topical treatment for positive margins after MMS, with an absolute difference of 9.9%. These findings support curettage as the preferred initial management approach for positive margins after MMS when clinically feasible.
PMID:
42536405
Bibliographic data and abstract were imported from PubMed on 31 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0